Scaling in vivo pharmacokinetics from in vitro metabolic stability data in drug discovery

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 2, 2010, Pages 159-169

  Klopf, Wendy ^a   Worboys, Philip ^a  

^a THERAVANCE INC   (United States)

Author keywords

Intrinsic clearance; Metabolic stability; Pharmacokinetics

Indexed keywords

DRUG METABOLITE;

AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; LIVER BLOOD FLOW; LIVER CLEARANCE; METABOLIC CLEARANCE RATE; METHODOLOGY; MICHAELIS CONSTANT; PRIORITY JOURNAL; REVIEW; SIMULATION;

ANIMALS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 77949807460     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710790596790     Document Type: Review

References (39)

1. Houston, J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol., 1994, 47, 1469-1479.
2. Saville, B.A.; Gray, M.R.; Tam, Y.K. Models of hepatic drug elimination. Drug Met. Rev., 1992, 24, 49-88.
3. Ito, K.; Houston, J.B. Comparison of the use of liver models for predicting drug clearance using iv vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res., 2004, 21, 785-792.
4. Worboys P.D.; Bradbury, A.; Houston J.B. Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and lowc-learance compounds. Drug Metab. Dispos., 1995, 23, 393-397.
5. Houston, J.B.; Carlile, D.J. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Met. Rev., 1997, 29, 891-922.
6. McGinnity, D.F.; Parker, A.J.; Soars, M.; Riley, R.J. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab. Dispos., 2000, 28, 1327-1334.
7. Venkatakrishnan, K.; Von Moltke, L.L.; Greenblatt, D.J. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate J. Pharmacol. Exp. Ther., 2001, 297, 326-337.
8. Barter, Z.E.; Bayliss, M.K.; Beaune, P.H.; Boobis, A.R.; Carlile, D.J.; Edwards, R.J.; Houston, J.B.; Lake, B.G.; Lipscomb, J.C.; Pelkonen, O.R.; Tucker, G.T.; Rostami-Hodjegan, A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human micro-somal protein and hepatocellularity per gram of liver Curr. Drug Metab., 2007, 8, 33-45.
9. Ito, K.; Houston, J.B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res., 2005, 22, 103-112.
10. Obach, R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of iv vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 1999, 27, 1350-1359.
11. Carlson, T.J.; Fisher, M.B. Recent advances in high throughput screeing for ADME properties. Comb. Chem. High Throughput Screen., 2008, 11, 258-264.
12. Obach, R.S.; Baxter, J.G.; Liston, T.E.; Silber, B.M.; Jones, B.C.; MacIntyre, F.; Rance, D.J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharm. Exp. Ther., 1997, 283, 46-58.
13. Fagerholm, U. Prediction of human pharmacokinetics - renal metabolic and excretion clearance. J. Pharmacy Pharmcol., 2007, 59, 1463-1471.
14. Soars, M.G.; Burchell, B.; Riley, R.J. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J. Exp. Pharmacol. Exp. Ther., 2002, 301, 382-390.
15. Boase, S.; Miners, J.O. In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br. J, Clin. Pharmacol., 2002, 54, 493-503.
16. Griffin, S.J.; Houston, J.B. Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of iv vitro intrinsic clearance. Drug Metab. Dispos., 2004, 32, 552-558.
17. Fagerholm, U. Prediction of human pharmacokinetics - improving microsome-based predictions of hepatic metabolic clearance. J. Pharmacy Pharmacol., 2007, 59, 1427-1431.
18. McLure, J.A.; Miners, J.O.; Birkett, D.J. Nonspecific binding of drugs to human liver microsomes. Br. J. Clin. Pharmacol., 2000, 49, 453-461.
19. Kalvass, J.C.; Tess, D.A.; Giragossian, C.;Linhares, M.C.; Maurer, T.S. Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling iv vitro data. Drug Metab. Dispos., 2001, 29, 1332-1336.
20. Austin, R.P.; Barton, P.; Cockroft, S.L.; Wenlock, M.C., Riley, R.J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos., 2002, 30, 1497-1503.
21. Lu, C.; Li, P.; Gallegos, R.; Uttamsingh, V.; Xia, C.Q., Miwa, G.T.; Balani, S.K., Gan, L.-S. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab. Dispos., 2006, 34, 1600-1605.
22. De Buck, S.S.; Sinha, V.K.; Fenu, L.A.; Gilissen, R.A.; Mackie, C.E.; Nijsen, M.J. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab. Dispos., 2007, 35, 649-659.
23. Hallifax, D.; Houston, J.B. Binding of drugs to hepatic microsomes: Comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab. Dispos., 2006, 34, 724-726.
24. Gertz, M.; Kilford, P.J.; Houston, J.B.; Galetin, A. Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab. Dispos., 2008, 36, 535-542.
25. Blanchard, N.; Hewitt, N.J.; Silber, P.; Jones, H.; Coassolo, P.; Lavé, T. Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations. J. Pharmacy Pharmacol., 2006, 58, 633-641.
26. Skaggs, S.M.; Foti, R.S.; Fisher, M.B. A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma. J. Pharmac. Toxicol. Meth., 2006, 53, 284-290.
27. Giuliano, C.; Jairaj, M.; Zafiu, C.M.; Laufer, R. Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab. Dispos., 2005, 33, 1319-1324.
28. Klopf, W.L.; Monshouwer, M.; Fretland, A.J. The development of an early and rapid screening assay to assess the unbound intrinsic clearance in micorosomes. Land O' Lakes Conference on Drug Metabolism/Applied Pharmacokinetics. 2007, Poster #127.
29. Uchimura, T.; Kato, M.; Tachibana, T.; Arai, S.; Nabuchi, Y.; Saito, K.; Kinoshita, H. New method for the simultaneous estimation of intrinsic hepatic clearance and protein binding by matrix inhibition. Biopharm. Drug Dispos., 2008, 29, 7-16.
30. Worboys, P.D.; Bradbury, A.; Houston, J.B. Kinetics of drug metabolism in Rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes. Drug Metab. Dispos., 1996, 24, 676-681.
31. Carlile, D.J.; Hakooz, N.; Bayliss, M.K.; Houston, J.B. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br. J. Clin. Pharmacol., 1999, 47, 625-635.
32. Obach, R.S.; Reed-Hagen, A.E. Measurement of michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab. Dispos., 2002, 30, 831-837.
33. Carlile, D.J.; Zomorodi, K.; Houston, J.B. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab. Dispos., 1997, 25, 903-911.
34. Mohutsky, M.A.; Chien, J.Y.; Ring, B.J.; Wrighton, S.A. Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. Pharm. Res., 2006, 23, 654-662.
35. Rodrigues, A.D. Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective. Pharm. Res., 1997, 14, 1504-1510.
36. Thompson, T.N. Early ADME in support of drug discovery: The role of metabolic stability studies. Current Drug Metab., 2000, 1, 215-241.
37. Drexler, D.M.; Belcastro, J.V.; Dickinson, K.E.; Edinger, K.J.; Hnatyshyn, S.Y.; Josephs, J.L.; Langish, R.A.; McNaney, C.A.; Santone, K.S.; Shipkova, P.E.; Tymiak, A.A.; Zvyaga, T.A.; Sanders, M. An automated high throughput liquid chromatography-mass spectrometry process to assess the metabolic stability of drug candidates. Assay Drug Dev. Tech., 2007, 5, 247-264.
38. Jacobson, L.; Middleton, B.; Holmgren, J.; Eirefelt, S.; Fröjd, M.; Blomgren, A.; Gustavsson, L. An optimized automated assay for determination of metabolic stability using hepatocytes: assay validation, variance component analysis, and in vivo relevance. Assay Drug Dev. Tech., 2007, 5, 403-415.
39. McNaney, C.A.; Drexler, D.M.; Hnatyshyn, S.Y.; Zvyaga, T.A.; Knipe, J.O.; Belcastro, J.V.; Sanders, M. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev. Tech., 2008, 6, 121-129.